- Home
- MRBK vs OBIO Comparison
MRBK vs OBIO Comparison
Compare MRBK & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRBK
- OBIO
- Stock Information
- Founded
- MRBK 2004
- OBIO 2017
- Country
- MRBK United States
- OBIO United States
- Employees
- MRBK N/A
- OBIO N/A
- Industry
- MRBK Major Banks
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- MRBK Finance
- OBIO Health Care
- Exchange
- MRBK Nasdaq
- OBIO Nasdaq
- Market Cap
- MRBK 159.8M
- OBIO 156.6M
- IPO Year
- MRBK 2017
- OBIO N/A
- Fundamental
- Price
- MRBK $15.36
- OBIO $5.17
- Analyst Decision
- MRBK Buy
- OBIO Strong Buy
- Analyst Count
- MRBK 2
- OBIO 5
- Target Price
- MRBK $16.00
- OBIO $15.80
- AVG Volume (30 Days)
- MRBK 36.8K
- OBIO 182.8K
- Earning Date
- MRBK 01-28-2025
- OBIO 11-12-2024
- Dividend Yield
- MRBK 3.21%
- OBIO N/A
- EPS Growth
- MRBK N/A
- OBIO N/A
- EPS
- MRBK 1.00
- OBIO N/A
- Revenue
- MRBK $92,357,000.00
- OBIO $2,647,000.00
- Revenue This Year
- MRBK N/A
- OBIO $22.61
- Revenue Next Year
- MRBK $10.48
- OBIO $16.64
- P/E Ratio
- MRBK $15.48
- OBIO N/A
- Revenue Growth
- MRBK N/A
- OBIO N/A
- 52 Week Low
- MRBK $8.26
- OBIO $3.96
- 52 Week High
- MRBK $17.33
- OBIO $9.65
- Technical
- Relative Strength Index (RSI)
- MRBK 62.38
- OBIO 48.86
- Support Level
- MRBK $13.56
- OBIO $5.00
- Resistance Level
- MRBK $15.42
- OBIO $5.70
- Average True Range (ATR)
- MRBK 0.41
- OBIO 0.57
- MACD
- MRBK 0.21
- OBIO 0.03
- Stochastic Oscillator
- MRBK 90.60
- OBIO 51.71
About MRBK Meridian Corporation
Meridian Corp is a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three business segments including Bank, Wealth, and Mortgage. It generates maximum revenue from the Bank segment that consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans, resulting in the generation of net interest income, and other sources.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.